Home Newsfeeds Cowen & Co. Maintains Outperform on Lyft, Lowers Price Target to $36

Cowen & Co. Maintains Outperform on Lyft, Lowers Price Target to $36

Cowen & Co. analyst John Blackledge maintains Lyft (NASDAQ:LYFT) with a Outperform and lowers the price target from $42 to $36.

byBenzinga Newsdesk

November 8, 2022

1 minute read

Cowen & Co. analyst John Blackledge maintains Lyft (NASDAQ:LYFT) with a Outperform and lowers the price target from $42 to $36.

Jaguar Health Announces Submission Of Clinical Trial Applications For Crofelemer To Treat Rare Disease Indications Microvillus Inclusion Disease And Short Bowel Syndrome In Europe

By Benzinga Newsdesk

May 9, 10:40 AM

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBSSAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / Jaguar

JAGX

Kura Oncology’s Head & Neck Cancer Candidate Shows Meaningful Antitumor Activity In Pretreated Patients

By Vandana Singh

October 18, 11:12 AM

Kura Oncology Inc (NASDAQ: KURA) announced results from its registration-directed AIM-HN study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease is recurrent or metastatic (R/M) and

KURA

Dow Dips 200 Points; Goldman Sachs Earnings Top Views

By Avi Kapoor

January 16, 10:49 AM

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.56% to 37,384.20 while the NASDAQ fell 0.69% to 14,869.02. The S&P 500 also fell, dropping, 0.53% to 4,758.60.

ALLK

Cidara Therapeutics Announces Divestiture Of Rezafungin To Mundipharma To Focus On Advancing The Clinical Development Of Cloudbreak DFC Pipeline; Transaction Provides Company With An Estimated ~$128M In Cost Savings

By Benzinga Newsdesk

April 24, 4:46 PM

Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an additional

CDTX

Cowen & Co. Maintains Outperform on Lyft, Lowers Price Target to $36

Related Posts

Jaguar Health Announces Submission Of Clinical Trial Applications For Crofelemer To Treat Rare Disease Indications Microvillus Inclusion Disease And Short Bowel Syndrome In Europe

Kura Oncology’s Head & Neck Cancer Candidate Shows Meaningful Antitumor Activity In Pretreated Patients

Dow Dips 200 Points; Goldman Sachs Earnings Top Views

Cidara Therapeutics Announces Divestiture Of Rezafungin To Mundipharma To Focus On Advancing The Clinical Development Of Cloudbreak DFC Pipeline; Transaction Provides Company With An Estimated ~$128M In Cost Savings